 BOSTON--BUSINESS WIRE--AVEO Oncology Nasdaq:AVEO today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEOs commercial strategy and operations, including the commercialization of FOTIVDA tivozanib. FOTIVDA is AVEOs differentiated oral, once-daily, vascular endothelial growth factor receptor VEGFR tyrosine kinase inhibitor TKI approved in the U.S. for the treatment of adult patients with relapsed or refractor 